5 major drug bathe 4 plus 7 after part of the original research drug was injured

5 major drugs "bully screen", Fujian hospital favors the original research drugs and slow disease drugs
December 4, Fujian Province pharmaceutical procurement platform announced the province's October 2019 "drug joint price limit Sunshine procurement drug sales amount ranked 20 in the top 20." Since January 2018, the province has announced a 22-month drug sales amount of TOP20, involving a total of 440 drugs (in terms of the name of the drug plus specifications and enterprises)Figure 1:440 Chinese-made and imported440 drugs, 296 are products of multinational pharmaceutical enterprises, accounting for 67.26%; In terms of drug type, chemicals dominated, accounting for 87.27%, followed by therapeutic biological products, accounting for 12.5%, musk heart-protection pills were the only Chinese medicine on the list, and only once in June 2019, ranked eighthFigure 2:440 drug treatment categories
440 drugs cover 8 major therapeutic areas, cardiovascular system drugs, systemic anti-infective drugs, anti-tumor and immunomodulators, digestive system and metabolic drugs accounted for more than 10%, it can be seen that Medical institutions in Fujian Province to chronic diseases, common diseases, multiple morbidity and other categories, which also determine the province's use of pharmaceutical forms to oral preparations (tablets, capsules, etc.) and injections, accounted for 51.82%, 48.88%, respectivelyTable 1: Top20 more than 10 times18 drugs for Fujian Province in the past 22 months sales amount of TOP20 "regular customers", the number of times on the list more than 12 times, Pfizer's injection of cephalosporine sodium sabatan sodium, Antibiticos Brasil Ltda injection with cephalosporine, Bayer's nitrobenzene flat control Release tablets, AstraZeneca's inhalation with buddinid fluid, Sanofi's glycosdelicate insulin injection 5 drug strong "bully screen", for 22 consecutive months on the list, including Pfizer's injection of cephalosporine sodium sodium shubatan for 5 months to pped the list, 12 months ranked second, an average of 2.68injected with cephalosporine subatan sodium belongs to the third generation of cephalosporins antibiotics, with broad-spectrum anti-gram-negative bacteria and partial gram-positive bacteriaAccording to minet data, in 2018, sales of sodium sodium subatan injection with cephalosporine in China's urban public hospitals, county-level public hospitals, urban community centers and township health centers (referred to as China's public medical institutions) amounted to 2.498 billion yuan4 plus 7 after part of the original research drug "injured", Xinlitai, Howson "upper"May 21, 2019, Fujian Provincial Health and Health Commission issued a notice, requiring the province to follow up the 4 plus 7, and from June 1 to implementAs a result, the ranking pattern of drug sales in the province has changed no smallTable 2: Part 4 and 7 varieties in Fujian Province sales amount rankingnote: not entered the TOP20 symbol srepresentative; The comparison of data for different months shows that there have been significant changes in the ranking of some 4 plus 7 varieties the first round of the 4 plus 7 episodes, Jialin Pharmaceuticals won the bid for atovastatine calcium tablets Prior to the implementation of the 4 plus 7 in Fujian Province, Pfizer and Lepp pharmaceutical products have been on the top of the list, the original research drug even for several months to win the top spot After June 2019, the original drug ranking dropped significantly, gradually withdrawing from TOP20, while Lepp pharmaceutical products completely withdrew from TOP20 Figure 3: 2013-2019 (first three quarters) Fujian Province public hospital terminal Atvastatin calcium tablet sales (unit: million yuan) meters net data show that in the first three quarters of 2019, Fujian Province public hospital terminal atautovastatin calcium tablets sales of no more than 50 million yuan, of which the third quarter sales of only 13.43 million yuan, can be seen 4 and 7 sets of drug sales have a huge impact at present in the domestic market, hydrogen sulphate chloropidogre tablets present the original research drug Sanofi, Xinlitai, Lepu, stone medicine four competition situation Before June 2019, the original research medicine, Lepu pharmaceutical products are basically within TOP20, and Xinlitai's products have not been listed In the first round of the 4 plus 7 sets, Xinlitai won the bid, Fujian executed 4 plus 7, the original research drug and the non-winning product fell out of TOP20, and Xinlitai by virtue of the winning bid advantage, for many months in a row on the list Pfizer's benzoic acid chlorpyrifos also exited TOP20 after June 2019 due to the first round of 4 plus 7 episodes, and another 4 plus 7 varietie, Ao-Nitrogen flat, entered TOP20 with a winning bid advantage, which it did not make the list until June 2019 thus shows that the price reduction effect of the 4 plus 7 is not a rise in sales and a decrease in the amount of sales, there may be a decrease in the price, and sales volume, sales amount increaseatd at the same time With the landing of the 4 plus 7 expansion and the continuous promotion of national collection, the sales pattern of various varieties in Fujian Province is bound to show more changes, the inner net will continue to follow up special procurement and medical insurance negotiations, to promote large-scale anti-tumor drugs Table 3: Some anti-tumor drugs in Fujian Province sales amount ranking note: not entered the TOP20 symbol s Six drugs were included in the national health insurance catalogue through negotiation, including 15 anti-tumor drugs, including Roche's "troika" rituxima, bevalbead monoantigen, quto-bead monoantigen and recombinant human endothelial inhibitor injections from the pre-acoustic pharmaceutical industry Figure 4: 2017-2019 (the first three quarters) Fujian Province public hospital terminal injection with qutobeu single anti-sales situation (unit: million yuan) Roche's "troika" from the 2018 began to have different degrees of release, especially injection with quto-bead mono-resistance, once ranked first in Fujian drug sales amount TOP20 According to Minenet, Roche's Quto Bead single resistance in 2018 was significant, up 454.83 percent year-on-year, and sales in the first three quarters of 2019 were higher than last year's for the whole of last year October 10, 2018, Oxitini, Azastine and other 17 kinds of anti-cancer drugs through negotiations into the national health insurance directory, an average price reduction of 56.7%; In July 2019, Ositini made the top of the top 20 for the sale of drugs in Fujian province, and then gradually moved forward Figure 5: 2018-2019 (first three quarters) Fujian Province public hospital terminal sudriating of the osulphate Oxitinib tablets (units: million yuan) Oxitini for the third generation of EGFR-TKI targeted drugs, known as "lung cancer medicine", was approved in March 2017, in October 2018 into the national health insurance In the first three quarters of 2019, sales of methiosulphic Oxitinib tablets at the end of Fujian's public hospitals were close to 50 million yuan, according to Minenet September 5, 2018, Fujian Province issued a special centralized procurement of anti-cancer drugs notice, in January, April and July 2019 has announced three batches of anti-cancer drugs special centralized procurement of linked products notice, with the continued promotion of this policy, the future or will be more and more anti-tumor drugs into its sales amount TOP20 list conclusion Fujian Province is the first to establish a comprehensive medical reform pilot, emerged a large number of medical reform samples, from the nearly 22 months of its drug sales amount TOP20, in the 4 plus 7 sets of harvest, national health insurance negotiations and other policies, its drug sales pattern has undergone a marked change, pharmaceutical enterprises should follow the trend, in advance to do a good job of layout! source: Mi net database, Fujian Province pharmaceutical procurement platform note: data statistics as of December 23, if there are omissions, welcome to point the finger! original title: 5 drugs "bully screen", this injection is bright! Medical reform of the province's drug sales change day, Xinlitai, Howson "top"